Table 2.
Clinical characteristics of H1RA responders and H1RA non-responders among CSU patients
| Characteristics | H1RA responders (n = 169) | H1RA non-responders (n = 113) | p value |
|---|---|---|---|
| Age (years) | 42.3 ± 12.0 | 42.6 ± 11.4 | 0.665 |
| Female n (%) | 111 (65.7) | 73 (64.6) | 0.852 |
| BMI (Kg/m2) | 23.4 ± 4.1 | 23.6 ± 3.6 | 0.577 |
| Urticaria duration (months) | 28.8 ± 56.8 | 22.1 ± 43.0 | 0.289 |
| UAS7 (0–42) | 24.4 ± 10.3 | 28.8 ± 9.3 | < 0.001 |
| Log[Total IgE (kU/L)] | 2.07 ± 0.5 | 2.13 ± 0.5 | 0.414 |
| ECP (kU/L) | 20.8 ± 16.5 | 23.1 ± 22.4 | 0.956 |
| Total cholesterol (mg/dL) | 194.8 ± 37.1 | 195.5 ± 36.3 | 0.985 |
| Triglycerides (ng/dL) | 148.7 ± 108.3 | 153.5 ± 84.8 | 0.288 |
| LDL (mg/dL) | 113.0 ± 37.8 | 110.7 ± 31.2 | 0.909 |
| HDL (mg/dL) | 56.1 ± 14.8 | 55.5 ± 15.3 | 0.862 |
| Platelet (*1000/μL) | 262.8 ± 56.7 | 263.0 ± 56.3 | 0.654 |
| Mean platelet volume | 8.0 ± 0.8 | 8.0 ± 0.7 | 0.544 |
| Complement 3 (mg/dL) | 108.6 ± 17.6 | 112.2 ± 24.7 | 0.525 |
| Complement 4 (mg/dL) | 26.3 ± 7.4 | 27.0 ± 8.6 | 0.481 |
| H1RA dosea (mg/day) | 21.0 ± 9.4 | 30.8 ± 13.3 | < 0.001 |
| Steroid use (%) | 88 (52.1) | 106 (93.8) | < 0.001 |
| Cyclosporine use (%) | 0 | 35 (31.0) | < 0.001 |
| Omalizumab use (%) | 0 | 38 (33.6) | < 0.001 |
| PAF (pg/ml) | 3804.6 [17.0–11716.4] | 5426.4 [53.2–14768.3] | < 0.001 |
| PAF-AH (ng/ml) | 104.2 [2.6–296.5] | 112.1 [4.4–256.9] | 0.051 |
p values were obtained by Pearson’s Chi square test for categorical variables and Mann–Whitney U-test for continuous variables
Medication score, daily mean loratadine dose to control symptoms
H1RA histamine receptor 1 antagonist, CSU chronic spontaneous urticaria, BMI body mass index, UAS7 sum of daily urticaria activity scores during the last week, ASST autologous serum skin test, ANA anti-nuclear antibody, ECP eosinophilic cationic protein, LDL low density lipoprotein, HDL high density lipoprotein, PAF platelet activating factor, PAF-AH platelet activating factor acetylhydrolase
aH1RA dose is presented as the mean daily H1RA prescription calculated as the loratadine equivalent dose for 3 months